Cargando…

JAK inhibitor, a new player for treatment-refractory microscopic colitis

Detalles Bibliográficos
Autores principales:	Druez, Anne, Travis, Simon, Rahier, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397550/ https://www.ncbi.nlm.nih.gov/pubmed/37394417 http://dx.doi.org/10.5217/ir.2023.00030

Ejemplares similares

Letter to the editor: response to ‘Epidemiology and seasonal pattern in hospitalizations for microscopic colitis’
por: Sohal, Aalam, et al.
Publicado: (2022)

JAK inhibitors for refractory lymphoma
por: Kimura, Hiroshi
Publicado: (2018)

Response to “Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis”
por: van Turenhout, Sietze, et al.
Publicado: (2021)

A new player in psoriatic arthritis: a JAK inhibitor
por: Sakkas, Lazaros I.
Publicado: (2017)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
por: Agrawal, Manasi, et al.
Publicado: (2020)

SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites
por: Gao, Yuan, et al.
Publicado: (2021)

Histopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutation
por: Duarte, Fernando Barroso, et al.
Publicado: (2014)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

Many questions raised by a question on JAK1/2 inhibitors in primary myelofibrosis
por: Raut, Lalit
Publicado: (2013)

Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer
por: Rahier, Jean-François, et al.
Publicado: (2017)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
por: Corrigan, Margaret, et al.
Publicado: (2019)

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor
por: Nie, Guangyan, et al.
Publicado: (2021)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Is Microscopic Colitis Really Microscopic?
por: Park, Young Sook, et al.
Publicado: (2015)

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor
por: Zhang, Huifang, et al.
Publicado: (2020)

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase
por: Chakraborty, S, et al.
Publicado: (2013)

Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib
por: Yang, Qiao, et al.
Publicado: (2018)

Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis
por: Fredrick, Thomas W, et al.
Publicado: (2022)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
por: Govaerts, Inge, et al.
Publicado: (2019)

Late and acute reaction to iohexol, refractory to treatment
por: Choudhury, Minati, et al.
Publicado: (2011)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

The coronary sinus reducer for the treatment of refractory angina
por: Paz, Y., et al.
Publicado: (2016)

Use of Budesonide in the Treatment of Microscopic Colitis
por: Tangri, Vikram, et al.
Publicado: (2010)

Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021)

CEBPA-regulated lncRNAs, new players in the study of acute myeloid leukemia
por: Hughes, James M, et al.
Publicado: (2014)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Microbial Associations With Microscopic Colitis
por: Sun, Shan, et al.
Publicado: (2022)

Listeria Meningitis during Infliximab-based Treatment for Ulcerative Colitis
por: Tsuchiya, Atsunori, et al.
Publicado: (2018)

Remote Control and Monitoring of Microscopic Slides
por: SHERAZ, Faizan, et al.
Publicado: (2016)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

The JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
por: de Freitas, Renata Mendes, et al.
Publicado: (2013)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Tools for managing IBD in obese patients: Get JAK in the box!
por: Alrammah, Hanan M., et al.
Publicado: (2021)

Refractory Checkpoint Inhibitor Colitis Responsive to Ustekinumab
por: Perez Del Nogal, Genesis, et al.
Publicado: (2022)

Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
por: Colombel, Jean-Frédéric
Publicado: (2018)

Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer
por: Zhang, Yi, et al.
Publicado: (2021)

Controversials of Microscopic Colitis
por: Mihaly, Emese, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2j58uhrkbpn5ssbujjj8ivmsea